Heart Septal Defects, Atrial
15
0
1
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
6.7%
1 terminated out of 15 trials
90.0%
+3.5% vs benchmark
27%
4 trials in Phase 3/4
22%
2 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (15)
Safety and Efficacy Study of Absnow Absorbable ASD Closure System For Treating ASD Patients
Study on the Safety and Effectiveness of a Biodegradable Patent Foramen Ovale Occluder System
Beta-blockers for Prevention of Supraventricular Arrhythmia Following PFO Closure
Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD
MitraClip® and Hemodynamic Effects of Relevant Iatrogenic Atrial Septum Defect Closure
The Effect on EPCs by Successful Cardiac Occlusion Device Implantation
ESCAPE Migraine Trial
Comparative Effects of Dexmedetomidine and Ketofol for Sedation in Patients Undergoing Trans-esophageal Echocardiography
Fluid Balance During Closure of Atrial Septal Defect
Molecular Genetic Epidemiology of Endocardial Cushion Defects - SCOR in Pediatric Cardiovascular Disease
Molecular Genetic Epidemiology of Three Cardiac Defects -SCOR in Pediatric Cardiovascular Disease
Reproduction and Survival After Cardiac Defect Repair
Bosentan for Mild Pulmonary Vascular Disease in Asd Patients.
Procedural Success and Safety of the Nit-Occlud® Patent Foramen Ovale (PFO) Closure Device and Its Application System
PC-Trial: Patent Foramen Ovale and Cryptogenic Embolism